---
title: "Wegovy (semaglutide), all indications: Specific populations questions"
description: "Specific populations questions on Wegovy (semaglutide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Can Wegovy be used during pregnancy? How long before pregnancy should Wegovy be stopped? Can Wegovy be used while breastfeeding? Can people with kidney or liver disease take Wegovy? 4 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/wegovy/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Wegovy (semaglutide), all indications: Specific populations questions

Manufacturer: Novo Nordisk Inc.  
Prescribing information: [Wegovy](https://www.novo-pi.com/wegovy.pdf)  
Indication pages: [Chronic weight management](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management)

## Specific populations

<a id="wegovy-pregnancy"></a>

### Can Wegovy be used during pregnancy?

> “Based on animal reproduction studies, there may be potential risks to the fetus from exposure to 
> semaglutide during pregnancy. Available pharmacovigilance data and data from clinical trials with 
> WEGOVY<sup>®</sup> use in pregnant patients are insufficient to establish a drug-associated risk of major birth 
> defects, miscarriage or adverse maternal or fetal outcomes.”

Source: [WEGOVY: Prescribing information, page 7, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=7)

> “Weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is 
> recognized, advise the pregnant patient of the risk to a fetus. Discontinue WEGOVY<sup>®</sup> in pregnant 
> patients who are using it for weight reduction (see Clinical Considerations).”

Source: [WEGOVY: Prescribing information, page 7, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=7)

> “Disease-Associated Maternal and/or Embryo/fetal Risk: Appropriate weight gain based on 
> pre-pregnancy weight is currently recommended for all pregnant patients, including those who 
> already have overweight or obesity, because of the obligatory weight gain that occurs in maternal 
> tissues during pregnancy.”

Source: [WEGOVY: Prescribing information, page 7, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=7)

> “There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to 
> WEGOVY<sup>®</sup> during pregnancy. Pregnant women exposed to WEGOVY<sup>®</sup> and healthcare providers are 
> encouraged to contact Novo Nordisk at 1-877-390-2760 or www.wegovypregnancyregistry.com.”

Source: [WEGOVY: Prescribing information, page 7, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=7)

<a id="wegovy-stop-before-pregnancy"></a>

### How long before pregnancy should Wegovy be stopped?

> “Because of the potential for fetal harm, discontinue WEGOVY<sup>®</sup> in patients at least 2 months before 
> they plan to become pregnant to account for the long half-life of semaglutide [see Use in Specific 
> Populations (8.1)].”

Source: [WEGOVY: Prescribing information, page 7, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=7)

<a id="wegovy-breastfeeding"></a>

### Can Wegovy be used while breastfeeding?

> “Lactation: A clinical lactation study reported semaglutide concentrations below the lower limit of quantification in human breast milk. However, salcaprozate sodium (SNAC) and/or its metabolites are present in human milk. Because of the unknown potential for serious adverse reactions in the breastfed infant due to the possible accumulation of SNAC, an absorption enhancer for Wegovy<sup>®</sup> tablets, and because there are alternative formulations of semaglutide that do not contain SNAC that can be used during lactation, advise patients that breastfeeding is not recommended during treatment with Wegovy<sup>®</sup> tablets”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=Lactation%3A%20A%20clinical%20lactation%20study,tablets)

> “WEGOVY<sup>®</sup> Subcutaneous Injection
> There are no data on the presence of subcutaneously administered semaglutide or its metabolites 
> in human milk, the effects on the breastfed infant, or the effects on milk production. WEGOVY<sup>®</sup> 
> subcutaneous injection does not contain the SNAC metabolites.
> The developmental and health benefits of breastfeeding should be considered along with the mother’s 
> clinical need for WEGOVY<sup>®</sup> and any potential adverse effects on the breastfed infant from WEGOVY<sup>®</sup> 
> or from the underlying maternal condition.”

Source: [WEGOVY: Prescribing information, page 7, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=7)

Note: The first passage concerns Wegovy tablets and the second Wegovy injection.

<a id="wegovy-kidney-liver-impairment"></a>

### Can people with kidney or liver disease take Wegovy?

> “Age, Sex, Race, Ethnicity, Body Weight, and Other Intrinsic Factors: No clinically significant differences 
> in semaglutide pharmacokinetics were observed based on age (<65 years, 65 to 74, ≥75 years old), 
> sex, race (White, Asian, or Black or African American), ethnicity, body weight, upper GI disease (i.e. 
> chronic gastritis and/or gastroesophageal reflux disease), renal impairment [estimated glomerular 
> filtration rate (eGFR) ≥30 to <90 mL/minute], or mild, moderate, and severe hepatic impairment 
> (Child-Pugh Class A-C) or fibrosis stage (F2 or F3 in patients with MASH).”

Source: [WEGOVY: Prescribing information, page 8, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=8)

> “The 
> risk of renal adverse reactions with WEGOVY<sup>®</sup> was increased in 
> adult patients with a history of renal impairment (trials included 
> 65 patients with a history of moderate or severe renal impairment 
> at baseline), and occurred more frequently during dose titration.”

Source: [WEGOVY: Prescribing information, page 6, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=6)

> “No limitations of use in patients with hepatic impairment”

Source: [WEGOVY: Wegovy® Side Effects & Safety Profile, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/safety-profile.html#:~:text=No%20limitations%20of%20use%20in%20patients%20with%20hepatic%20impairment)

On the page, select: Pill

## Related pages
- [Medical information: Wegovy (semaglutide): All indications](https://www.evicenter.com/medical-information/wegovy)
- [Indication](https://www.evicenter.com/medical-information/wegovy/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/wegovy/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/wegovy/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/wegovy/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/wegovy/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/wegovy/storage-and-supply)
